

Publications Hélène Blons

Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study.

Mehlman C, Cadranel J, Rousseau-Bussac G, Lacave R, Pujals A, Girard N, Callens C, Gounant V, Théou-Anton N, Friard S, Trédaniel J, Blons H, Dujon C, Duchemann B, Schischmanoff PO, Chinet T, Giroux Leprieur E.

Lung Cancer. 2019 Sep 28;137:149-156. doi: 10.1016/j.lungcan.2019.09.019. [Epub ahead of print]

PMID:31600593

Similar articles

Select item 314720132.

Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer.

Moati E, Blons H, Taly V, Garlan F, Wang-Renault SF, Pietrasz D, Didelot A, Garrigou S, Saint A, Pernot S, Taieb J, Laurent-Puig P, Zaanani A.

Int J Cancer. 2019 Aug 31. doi: 10.1002/ijc.32657. [Epub ahead of print]

PMID:31472013

Similar articles

Select item 313773473.

The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer.

Le Corre D, Ghazi A, Balogoun R, Pilati C, Aparicio T, Martin-Lannerée S, Marisa L, Djouadi F, Poindessous V, Crozet C, Emile JF, Mulot C, Le Malicot K, Boige V, Blons H, de Reynies A, Taieb J, Ghiringhelli F, Bennouna J, Launay JM, Laurent-Puig P, Mouillet-Richard S.

EBioMedicine. 2019 Aug;46:94-104. doi: 10.1016/j.ebiom.2019.07.036. Epub 2019 Jul 31.

PMID:31377347Free PMC Article

Similar articles

Select item 313195694.

BRAF Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGE0 RASANC Study.

Mas L, Bachet JB, Taly V, Bouché O, Taieb J, Cohen R, Meurisse A, Normand C, Gornet JM, Artru P, Louafi S, Thiot-Bidault A, Baumgaertner I, Coriat R, Tougeron D, Lecomte T, Mary F, Aparicio T, Marthey L, Blons H, Vernerey D, Laurent-Puig P.

Cancers (Basel). 2019 Jul 17;11(7). pii: E998. doi: 10.3390/cancers11070998.

PMID:31319569Free PMC Article

Similar articles

Select item 312810515.

Clinical Characteristics, Molecular Phenotyping, and Management of Isolated Adrenal Metastases From Lung Cancer.

Mazzella A, Loi M, Mansuet-Lupo A, Bobbio A, Blons H, Damotte D, Alifano M.

Clin Lung Cancer. 2019 Jun 13. pii: S1525-7304(19)30145-7. doi: 10.1016/j.clcc.2019.06.003. [Epub ahead of print]

PMID:31281051

Similar articles

Select item 311995806.

NF1 mutations identify molecular and clinical subtypes of lung adenocarcinomas.

Tlemsani C, Pécuchet N, Gruber A, Laurendeau I, Danel C, Riquet M, Le Pimpec-Barthes F, Fabre E, Mansuet-Lupo A, Damotte D, Alifano M, Luscan A, Rousseau B, Vidaud D, Varin J, Parfait B, Bieche I, Leroy K, Laurent-Puig P, Terris B, Blons H, Vidaud M, Pasmant E.

Cancer Med. 2019 Aug;8(9):4330-4337. doi: 10.1002/cam4.2175. Epub 2019 Jun 14.

PMID:31199580Free PMC Article

Similar articles

Select item 309126747.

DNAShell Protects DNA Stored at Room Temperature for Downstream Next-Generation Sequencing Studies.

Washetine K, Heeke S, Ribeyre C, Bourreau C, Normand C, Blons H, Laurent-Puig P, Mulot C, Clermont D, David M, Clément B, Dagher G, Hofman P.

Biopreserv Biobank. 2019 Aug;17(4):352-354. doi: 10.1089/bio.2018.0129. Epub 2019 Mar 26. No abstract available.

PMID:30912674

Similar articles

Select item 308635688.

How apoptosis and epithelial-to-mesenchymal transition are nested in EGFR inhibitors resistance in lung cancer.

Garinet S, Didelot A, Garelli E, Pallier K, Blons H, Legras A.

J Thorac Dis. 2019 Jan;11(1):47-49. doi: 10.21037/jtd.2018.12.117. No abstract available.

PMID:30863568Free PMC Article

Similar articles

Select item 307750259.

Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update.

Blons H, Garinet S, Laurent-Puig P, Oudart JB.

J Thorac Dis. 2019 Jan;11(Suppl 1):S25-S36. doi: 10.21037/jtd.2018.12.48. Review.

PMID:30775025Free PMC Article

Similar articles

Select item 3072179710.

Proposal for a Combined Histomolecular Algorithm to Distinguish Multiple Primary Adenocarcinomas from Intrapulmonary Metastasis in Patients with Multiple Lung Tumors.

Mansuet-Lupo A, Barritault M, Alifano M, Janet-Vendroux A, Zarmaev M, Biton J, Velut Y, Le Hay C, Cremer I, Régnard JF, Fournel L, Rance B, Wislez M, Laurent-Puig P, Herbst R, Damotte D, **Blons H**.

J Thorac Oncol. 2019 May;14(5):844-856. doi: 10.1016/j.jtho.2019.01.017. Epub 2019 Feb 2.

PMID:30721797

Similar articles

Select item 3067907911.

Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2).

Beau-Faller M, Texier M, Blons H, Richard N, Escande F, Melaabi S, Lizard S, De Fraipont F, Longchamp E, Morin F, Zalcman G, Pignon JP, Cadranet J.

Clin Lung Cancer. 2019 May;20(3):222-230. doi: 10.1016/j.clcc.2018.12.012. Epub 2018 Dec 19.

PMID:30679079

Similar articles

Select item 3035286912.

Chemoresistant pleomorphic rhabdomyosarcoma: whole exome sequencing reveals underlying cancer predisposition and therapeutic options.

Tlemsani C, Leroy K, Gimenez-Roqueplo AP, Mansuet-Lupo A, Pasmant E, Larousserie F, Boudou-Rouquette P, Vidaud M, Cadranet J, Blons H, Goldwasser F, Laurent-Puig P.

J Med Genet. 2018 Oct 23. pii: jmedgenet-2018-105594. doi: 10.1136/jmedgenet-2018-105594. [Epub ahead of print]

PMID:30352869

Similar articles

Select item 3034394513.

[IHC, FISH, CISH, NGS in non-small cell lung cancer: What changes in the biomarker era?]

Hamard C, Mignard X, Pecuchet N, Mathiot N, Blons H, Laurent-Puig P, Leroy K, Lupo A, Chapron J, Giraud F, Arrondeau J, Goldwasser F, Alifano M, Damotte D, Wislez M.

Rev Pneumol Clin. 2018 Oct;74(5):327-338. doi: 10.1016/j.pneumo.2018.09.013. Epub 2018 Oct 19. Review. French.

PMID:30343945

Similar articles

Select item 3012013714.

Vemurafenib and cobimetinib overcome resistance to vemurafenib in *BRAF*-mutant ganglioglioma.

Touat M, Gratioux J, Condette Auliac S, Sejean K, Aldea S, Savatovsky J, Perkins G, Blons H, Ligon KL, Idhah A, Hollebecque A, Gimenez-Roqueplo AP, Laurent-Puig P, Sanson M, Villa C, Di Stefano AL.

Neurology. 2018 Sep 11;91(11):523-525. doi: 10.1212/WNL.0000000000006171. Epub 2018 Aug 17. No abstract available.

PMID:30120137

Similar articles

Select item 3011502615.

Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study.

Vaughn CP, Costa JL, Feilotter HE, Petraroli R, Bagai V, Rachiglio AM, Marino FZ, Tops B, Kurth HM, Sakai K, Mafficini A, Bastien RRL, Reiman A, Le Corre D, Boag A, Crocker S, Bihl M, Hirschmann A, Scarpa A, Machado JC, Blons H, Sheils O, Bramlett K, Ligtenberg MJL, Cree IA, Normanno N, Nishio K, Laurent-Puig P.

BMC Cancer. 2018 Aug 16;18(1):828. doi: 10.1186/s12885-018-4736-4.

PMID:30115026Free PMC Article

Similar articles

Select item 2989076116.

Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?

Garinet S, Laurent-Puig P, Blons H, Oudart JB.

J Clin Med. 2018 Jun 9;7(6). pii: E144. doi: 10.3390/jcm7060144. Review.

PMID:29890761Free PMC Article

Similar articles

Select item 2985011117.

Clinical and molecular characteristics of unicentric mediastinal Castleman disease.

Legras A, Tallet A, Didelot A, Cazes A, Danel C, Hin A, Borie R, Crestani B, Castier Y, Bagan P, Le Pimpec-Barthes F, Riquet M, Blons H, Mordant P.

J Thorac Dis. 2018 Apr;10(4):2079-2088. doi: 10.21037/jtd.2018.03.159.

PMID:29850111Free PMC Article

Similar articles

Select item 2978786318.

Validity of Targeted Next-Generation Sequencing in Routine Care for Identifying Clinically Relevant Molecular Profiles in Non-Small-Cell Lung Cancer: Results of a 2-Year Experience on 1343 Samples.

Legras A, Barritault M, Tallet A, Fabre E, Guyard A, Rance B, Digan W, Pecuchet N, Giroux-Leprieur E, Julie C, Jouveshomme S, Duchatelle V, Giraudet V, Gibault L, Cazier A, Pastre J, Le Pimpec-Barthes F, Laurent-Puig P, **Blons H**.

J Mol Diagn. 2018 Jul;20(4):550-564. doi: 10.1016/j.jmoldx.2018.04.002. Epub 2018 May 19.

PMID:29787863

Similar articles

Select item 2976485619.

TP53, *STK11*, and *EGFR* Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma.

Biton J, Mansuet-Lupo A, Pécuchet N, Alifano M, Ouakrim H, Arrondeau J, Boudou-Rouquette P, Goldwasser F, Leroy K, Goc J, Wislez M, Germain C, Laurent-Puig P, Dieu-Nosjean MC, Cremer I, Herbst R, Blons H, Damotte D.

Clin Cancer Res. 2018 Nov 15;24(22):5710-5723. doi: 10.1158/1078-0432.CCR-18-0163. Epub 2018 May 15.

PMID:29764856

Similar articles

Select item 2972138820.

Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer.

Giroux Leprieur E, Herbretau G, Dumenil C, Julie C, Giraud V, Labrune S, Dumoulin J, Tisserand J, Emile JF, Blons H, Chinnet T.

Oncoimmunology. 2018 Jan 29;7(5):e1424675. doi: 10.1080/2162402X.2018.1424675. eCollection 2018.

PMID:29721388Free PMC Article

Similar articles

Select item 2962745321.

Role of circulating tumor DNA in the management of patients with colorectal cancer.

Moati E, Taly V, Didelot A, Perkins G, Blons H, Taieb J, Laurent-Puig P, Zaanan A.

Clin Res Hepatol Gastroenterol. 2018 Oct;42(5):396-402. doi: 10.1016/j.clinre.2018.03.002. Epub 2018 Apr 5. Review.

PMID:29627453

Similar articles

Select item 2954531822.

Cost-effectiveness of *KRAS*, *EGFR* and *ALK* testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study.

Loubière S, Drezet A, Beau-Faller M, Moro-Sibilot D, Friard S, Wislez M, Blons H, Daniel C, Westeel V, Madroszyk A, Léna H, Merle P, Mazières J, Zalcman G, Lacave R, Antoine M, Morin F, Missy P, Barlesi F, Auquier P, Cadranet J; French Cooperative Thoracic Intergroup (IFCT).

Eur Respir J. 2018 Mar 15;51(3). pii: 1701467. doi: 10.1183/13993003.01467-2017. Print 2018 Mar.

PMID:29545318Free Article

Similar articles

Select item 2943852223.

RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study.

Bachet JB, Bouché O, Taieb J, Dubreuil O, Garcia ML, Meurisse A, Normand C, Gornet JM, Artru P, Louafi S, Bonnetain F, Thiot-Bidault A, Baumgaertner I, Coriat R, Tougeron D, Lecomte T, Mary F, Aparicio T, Marthey L, Taly V, Blons H, Vernerey D, Laurent-Puig P.

Ann Oncol. 2018 May 1;29(5):1211-1219. doi: 10.1093/annonc/mdy061.

PMID:29438522

Similar articles

Select item 2938936024.

Transplantation of Human Embryonic Stem Cell-Derived Cardiovascular Progenitors for Severe Ischemic Left Ventricular Dysfunction.

Menasché P, Vanneaux V, Hagège A, Bel A, Cholley B, Parouchev A, Cacciapuoti I, Al-Daccak R, Benhamouda N, Blons H, Agbulut O, Tosca L, Trouvin JH, Fabreguettes JR, Bellamy V, Charron D, Tartour E, Tachdjian G, Desnos M, Larghero J.

J Am Coll Cardiol. 2018 Jan 30;71(4):429-438. doi: 10.1016/j.jacc.2017.11.047.

PMID:29389360Free Article

Similar articles

Select item 2911026225.

Mutational Diversity of Lung Cancer and Associated Lymph Nodes. An Exploratory Prospective Study of 4 Resected cIIIA-N2. Legras A, Roussel H, Mangiameli G, Arame A, Grand B, Pricopi C, Badia A, Gibault L, Badoual C, Fabre E, Laurent-Puig P, Blons H, Le Pimpec-Barthes F. *Pathol Oncol Res*. 2019 Jan;25(1):319-325. doi: 10.1007/s12253-017-0352-x. Epub 2017 Nov 6.

[Lynch syndrome and endometrial cancer]. Bats AS, Rossi L, Le Frere-Belda MA, Narjoz C, Cournou C, Gosset M, Ngo C, Delomenie M, Nos C, Blons H, Laurent-Puig P, Lecuru F. *Bull Cancer*. 2017 Dec;104(12):1013-1021. doi: 10.1016/j.bulcan.2017.06.018. Epub 2017 Oct 21. Review. French.

An architecture for genomics analysis in a clinical setting using Galaxy and Docker. Digan W, Countouris H, Barritault M, Baudoin D, Laurent-Puig P, Blons H, Burgun A, Rance B. *Gigascience*. 2017 Nov 1;6(11):1-9. doi: 10.1093/gigascience/gix099.

Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program. Leduc C, Merlio JP, Besse B, Blons H, Debieuvre D, Bringuier PP, Monnet I, Rouquette I, Fraboulet-Moreau S, Lemoine A, Pouessel D, Mosser J, Vaylet F, Langlais A, Missy P, Morin F, Moro-Sibilot D, Cadranet J, Barlesi F, Beau-Faller M; French Cooperative Thoracic Intergroup (IFCT). *Ann Oncol*. 2017 Nov 1;28(11):2715-2724. doi: 10.1093/annonc/mdx404.

Epithelial-to-Mesenchymal Transition and MicroRNAs in Lung Cancer. Legras A, Pécuchet N, Imbeaud S, Pallier K, Didelot A, Roussel H, Gibault L, Fabre E, Le Pimpec-Barthes F, Laurent-Puig P, **Blons H**. *Cancers (Basel)*. 2017 Aug 3;9(8). pii: E101. doi: 10.3390/cancers9080101. Review.

Morphologic and molecular study of lung cancers associated with idiopathic pulmonary fibrosis and other pulmonary fibroses. Guyard A, Danel C, Théou-Anton N, Debray MP, Gibault L, Mordant P, Castier Y, Crestani B, Zalcman G, Blons H, Cazes A. *Respir Res*. 2017 Jun 15;18(1):120. doi: 10.1186/s12931-017-0605-y.

Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study). Garlan F, Laurent-Puig P, Sefrioui D, Siauve N, Didelot A, Sarafan-Vasseur N, Michel P, Perkins G, Mulot C, Blons H, Taieb J, Di Fiore F, Taly V, Zaanani A. *Clin Cancer Res*. 2017 Sep 15;23(18):5416-5425. doi: 10.1158/1078-0432.CCR-16-3155. Epub 2017 Jun 2.

Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy. Roussel H, De Guillebon E, Biard L, Mandavit M, Gibault L, Fabre E, Antoine M, Hofman P, Beau-Faller M, Blons H, Danel C, Barthes FLP, Gey A, Granier C, Wislez M, Laurent-Puig P, Oudard S, Bruneval P, Badoual C, Cadranet J, Tartour E. *Oncoimmunology*. 2017 Feb 21;6(4):e1286437. doi: 10.1080/2162402X.2017.1286437. eCollection 2017.

Molecular classification of pulmonary sarcomatoid carcinomas suggests new therapeutic opportunities. Pécuchet N, Vieira T, Rabbe N, Antoine M, Blons H, Cadranet J, Laurent-Puig P, Wislez M. *Ann Oncol*. 2017 Jul 1;28(7):1597-1604. doi: 10.1093/annonc/mdx162.

Women Epidemiology Lung Cancer (WELCA) study: reproductive, hormonal, occupational risk factors and biobank. Stücker I, Martin D, Neri M, Laurent-Puig P, Blons H, Antoine M, Guiochon-Mantel A, Brailly-Tabard S, Canonico M, Wislez M, Trédaniel J; WELCA study group. *BMC Public Health*. 2017 Apr 17;17(1):324. doi: 10.1186/s12889-017-4191-1.

Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study. Pécuchet N, Zonta E, Didelot A, Combe P, Thibault C, Gibault L, Lours C, Rozenholc Y, Taly V, Laurent-Puig P, Blons H, Fabre E. PLoS Med. 2016 Dec 27;13(12):e1002199. doi: 10.1371/journal.pmed.1002199. eCollection 2016 Dec.

Analysis of Base-Position Error Rate of Next-Generation Sequencing to Detect Tumor Mutations in Circulating DNA. Pécuchet N, Rozenholc Y, Zonta E, Pietrasz D, Didelot A, Combe P, Gibault L, Bachet JB, Taly V, Fabre E, Blons H, Laurent-Puig P. Clin Chem. 2016 Nov;62(11):1492-1503. Epub 2016 Sep 13.

Multiplex Detection of Rare Mutations by Picoliter Droplet Based Digital PCR: Sensitivity and Specificity Considerations. Zonta E, Garlan F, Pécuchet N, Perez-Toralla K, Caen O, Milbury C, Didelot A, Fabre E, Blons H, Laurent-Puig P, Taly V. PLoS One. 2016 Jul 14;11(7):e0159094. doi: 10.1371/journal.pone.0159094. eCollection 2016.

Intratumoral Immune Cell Densities Are Associated with Lung Adenocarcinoma Gene Alterations. Mansuet-Lupo A, Alifano M, Pécuchet N, Biton J, Becht E, Goc J, Germain C, Ouakrim H, Régnard JF, Cremer I, Laurent-Puig P, Dieu-Nosjean MC, Blons H, Damotte D. Am J Respir Crit Care Med. 2016 Dec 1;194(11):1403-1412.

[Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA]. Pécuchet N, Legras A, Laurent-Puig P, **Blons H**. Ann Pathol. 2016 Jan;36(1):80-93. doi: 10.1016/j.annpat.2015.11.012. Epub 2016 Jan 20. French.

[What future for circulating tumor DNA? Current data and prospects in colorectal, non-small cell lung and pancreatic cancers]. Pietrasz D, Pécuchet N, Fabre E, Blons H, Chevalier L, Taly V, Laurent-Puig P, Bachet JB. Bull Cancer. 2016 Jan;103(1):55-65. doi: 10.1016/j.bulcan.2015.10.017. Epub 2016 Jan 11. Review. French.

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).

Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, Ouafik L, Besse B, Rouquette I, Westeel V, Escande F, Monnet I, Lemoine A, Veillon R, Blons H, Audigier-Valette C, Bringuier PP, Lamy R, Beau-Faller M, Pujol JL, Sabourin JC, Penault-Llorca F, Denis MG, Lantuejoul S, Morin F, Tran Q, Missy P, Langlais A, Milleron B, Cadranel J, Soria JC, Zalcman G; Biomarkers France contributors.

Lancet. 2016 Apr 2;387(10026):1415-1426. doi: 10.1016/S0140-6736(16)00004-0. Epub 2016 Jan 15.

Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial. Taieb J, Zaanani A, Le Malicot K, Julié C, Blons H, Mineur L, Bannoun J, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Lepage C, Emile JF, Laurent-Puig P. JAMA Oncol. 2016 May 1;2(5):643-653. doi: 10.1001/jamaoncol.2015.5225.

Three Rounds of External Quality Assessment in France to Evaluate the Performance of 28 Platforms for Multiparametric Molecular Testing in Metastatic Colorectal and Non-Small Cell Lung Cancer. Dequeker EM, Keppens C, Egele C, Delen S, Lamy A, Lemoine A, Sabourin JC, Andrieu C, Ligtenberg M, Fetique D, Tops B, Descarpentries C, Blons H, Denoux Y, Aube C, Penault-Llorca F, Hofman P, Leroy K, Le Marechal C, Doucet L, Duranton-Tanneur V, Pedetour F, Soubeyran I, Côté JF, Emile JF, Vignaud JM, Monhoven N, Haddad V, Laurent-Puig P, van Krieken H, Nowak F, Lonchamp E, Bellocq JP, Rouleau E. J Mol Diagn. 2016 Mar;18(2):205-14. doi: 10.1016/j.jmoldx.2015.09.004. Epub 2016 Jan 2.

Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer. Pécuchet N, Laurent-Puig P, Mansuet-Lupo A, Legras A, Alifano M, Pallier K, Didelot A, Gibault L, Danel C, Just PA, Riquet M, Le Pimpec-Barthes F, Damotte D, Fabre E, **Blons H**. Oncotarget. 2017 Apr 4;8(14):23831-23840. doi: 10.18632/oncotarget.6379.

Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation. Combe P, Chauvenet L, Lefrère-Belda MA, Blons H, Rousseau C, Oudard S, Pujade-Lauraine E. Invest New Drugs. 2015 Dec;33(6):1267-70. doi: 10.1007/s10637-015-0297-4. Epub 2015 Oct 21.

Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers. Harlé A, Salleron J, Perkins G, Pilati C, Blons H, Laurent-Puig P, Merlin JL. *Br J Cancer*. 2015 Aug 11;113(4):680-5. doi: 10.1038/bjc.2015.250. Epub 2015 Jul 14.

French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas. Lantuejoul S, Rouquette I, Blons H, Le Stang N, Ilie M, Begueret H, Grégoire V, Hofman P, Gros A, Garcia S, Monhoven N, Devouassoux-Shisheboran M, Mansuet-Lupo A, Thivolet F, Antoine M, Vignaud JM, Penault-Llorca F, Galateau-Sallé F, McLeer-Florin A. *Eur Respir J*. 2015 Jul;46(1):207-18. doi: 10.1183/09031936.00119914. Epub 2015 Apr 30.

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. Blons H, Emile JF, Le Malicot K, Julié C, Zaanani A, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Nørgård-Petersen L, Van Cutsem E, Lepage C, Zawadi MA, Salazar R, Laurent-Puig P, Taieb J; PETACC-8 Study Investigators. *Ann Oncol*. 2014 Dec;25(12):2378-85. doi: 10.1093/annonc/mdu464. Epub 2014 Oct 6. Erratum in: *Ann Oncol*. 2015 Apr;26(4):822-5.

Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer. Perkins G, Pilati C, Blons H, Laurent-Puig P. *Pharmacogenomics*. 2014 May;15(7):1043-52. doi: 10.2217/pgs.14.66. Review.

Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Petersen LN, Blons H, Collette L, Van Cutsem E, Rougier P, Salazar R, Bedenne L, Emile JF, Laurent-Puig P, Lepage C; PETACC-8 Study Investigators. *Lancet Oncol*. 2014 Jul;15(8):862-73. doi: 10.1016/S1470-2045(14)70227-X. Epub 2014 Jun 11.

Microsatellite instability analysis in uterine cavity washings to detect endometrial cancer in Lynch syndrome. Bats AS, Blons H, Narjoz C, Le Frere-Belda MA, Laurent-Puig P, Lecuru F. *Anticancer Res*. 2014 Jun;34(6):3211-5.

Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis? Mansuet-Lupo A, Zouiti F, Alifano M, Tallet A, Charpentier MC, Ducruit V, Devez F, Lemaitre F, Laurent-Puig P, Damotte D, **Blons H**. *J Transl Med*. 2014 May 16;12:131. doi: 10.1186/1479-5876-12-131.

ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy. Zaanani A, Dalban C, Emile JF, Blons H, Fléjou JF, Goumard C, Istanbulu M, Calmel C, Alhazmi K, Validire P, Louvet C, de Gramont A, Laurent-Puig P, Taïeb J, Praz F. *J Cancer*. 2014 May 2;5(6):425-32. doi: 10.7150/jca.8594. eCollection 2014.

ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma. Laforest A, Aparicio T, Zaanani A, Silva FP, Didelot A, Desbeaux A, Le Corre D, Benhaim L, Pallier K, Aust D, Pistorius S, Blons H, Svrcek M, Laurent-Puig P. *Eur J Cancer*. 2014 Jul;50(10):1740-1746. doi: 10.1016/j.ejca.2014.04.007. Epub 2014 May 2.

The new histologic classification of lung primary adenocarcinoma subtypes is a reliable prognostic marker and identifies tumors with different mutation status: the experience of a French cohort. Mansuet-Lupo A, Bobbio A, Blons H, Becht E, Ouakrim H, Didelot A, Charpentier MC, Bain S, Marmey B, Bonjour P, Biton J, Cremer I, Dieu-Nosjean MC, Sautès-Fridman C, Régnard JF, Laurent-Puig P, Alifano M, Damotte D. *Chest*. 2014 Sep;146(3):633-643. doi: 10.1378/chest.13-2499.

[Molecular profiling of non-small cell lung cancer]. Gibault L, Cazes A, Narjoz C, **Blons H**. *Rev Pneumol Clin*. 2014 Feb-Apr;70(1-2):47-62. doi: 10.1016/j.pneumo.2013.11.005. Epub 2014 Feb 22. Review. French.

Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Beau-Faller M, Prim N, Ruppert AM, Nanni-Metellus I, Lacave R, Lacroix L, Escande F, Lizard S, Pretet JL, Rouquette I, de Crémoux P, Solassol J, de Fraipont F, Bièche I, Cayre A, Favre-Guillevin E, Tomasini P, Wislez M, Besse B, Legrain M, Voegeli AC, Baudrin L, Morin F, Zalcman G, Quoix E, Blons H, Cadranet J. *Ann Oncol*. 2014 Jan;25(1):126-31. doi: 10.1093/annonc/mdt418. Epub 2013 Nov 26.

A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms. Beau-Faller M, Blons H, Domerg C, Gajda D, Richard N, Escande F, Solassol J, Denis MG, Cayre A, Nanni-Metellus I, Olschwang S, Lizard S, Piard F, Pretet JL, de Fraipont F, Bièche I, de Cremoux P, Rouquette I, Bringuier PP, Mosser J, Legrain M, Voegeli AC, Saulnier P, Morin F, Pignon JP, Zalcman G, Cadranet J. *J Mol Diagn*. 2014 Jan;16(1):45-55. doi: 10.1016/j.jmoldx.2013.07.009. Epub 2013 Oct 30.

Microsatellite instability analysis for the screening of synchronous endometrial and ovarian cancer in Lynch syndrome. Bats AS, Roussel H, Narjoz C, Le Frere-Belda MA, Chamming's F, Blons H, Laurent-Puig P, Lecuru F. *Anticancer Res*. 2013 Sep;33(9):3977-81.

Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Taly V, Pekin D, Benhaim L, Kotsopoulos SK, Le Corre D, Li X, Atochin I, Link DR, Griffiths AD, Pallier K, Blons H, Bouché O, Landi B, Hutchison JB, Laurent-Puig P. *Clin Chem*. 2013 Dec;59(12):1722-31. doi: 10.1373/clinchem.2013.206359. Epub 2013 Aug 12.

Performance and cost efficiency of KRAS mutation testing for metastatic colorectal cancer in routine diagnosis: the MOKAECM study, a nationwide experience. Blons H, Rouleau E, Charrier N, Chatellier G, Côté JF, Pages JC, de Fraipont F, Boyer JC, Merlio JP, Morel A, Gorisse MC, de Cremoux P, Leroy K, Milano G, Ouafik L, Merlin JL, Le Corre D, Aucouturier P, Sabourin JC, Nowak F, Frebourg T, Emile JF, Durand-Zaleski I, Laurent-Puig P; MOKAECM Collaborative Group. *PLoS One*. 2013 Jul 25;8(7):e68945. doi: 10.1371/journal.pone.0068945. Print 2013.

Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours. Cros J, Sbidian E, Hans S, Roussel H, Scotte F, Tartour E, Brasnu D, Laurent-Puig P, Bruneval P, Blons H, Badoual C. *Ann Oncol*. 2013 Oct;24(10):2624-9. doi: 10.1093/annonc/mdt338. Epub 2013 Aug 8.

EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients. Villalva C, Durantou-Tanneur V, Guilloteau K, Burel-Vandenbos F, Wager M, Doyen J, Levillain PM, Fontaine D, Blons H, Pedetour F, Karayan-Tapon L. *Cancer Med*. 2013 Jun;2(3):296-304. doi: 10.1002/cam4.82. Epub 2013 Apr 23.

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. Mazières J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, Besse B, Blons H, Mansuet-Lupo A, Urban T, Moro-Sibilot D, Dansin E, Chouaid C, Wislez M, Diebold J, Felip E, Rouquette I, Milia JD, Gautschi O. *J Clin Oncol*. 2013 Jun 1;31(16):1997-2003. doi: 10.1200/JCO.2012.45.6095. Epub 2013 Apr 22.

Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma. Andujar P, Pairon JC, Renier A, Descatha A, Hysi I, Abd-Alsamad I, Billon-Galland MA, Blons H, Clin B, Danel C, Debrosse D, Galateau-Sallé F, Housset B, Laurent-Puig P, Le Pimpec-Barthes F, Letourneux M, Monnet I, Régnard JF, Validire P, Zucman-Rossi J, Jaurand MC, Jean D. *Mutagenesis*. 2013 May;28(3):323-31. doi: 10.1093/mutage/get008. Epub 2013 Feb 22.

Multiplex picoliter-droplet digital PCR for quantitative assessment of DNA integrity in clinical samples. Didelot A, Kotsopoulos SK, Lupo A, Pekin D, Li X, Atochin I, Srinivasan P, Zhong Q, Olson J, Link DR, Laurent-Puig P, Blons H, Hutchison JB, Taly V. *Clin Chem*. 2013 May;59(5):815-23. doi: 10.1373/clinchem.2012.193409. Epub 2013 Feb 12.

Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. Colomba E, Hélias-Rodzewicz Z, Von Deimling A, Marin C, Terrones N, Pechaud D, Sural S, Côté JF, Peschaud F, Capper D, Blons H, Zimmermann U, Clerici T, Saiag P, Emile JF. *J Mol Diagn*. 2013 Jan;15(1):94-100. doi: 10.1016/j.jmoldx.2012.09.001. Epub 2012 Nov 15.

Colorectal neuroendocrine carcinomas and adenocarcinomas share oncogenic pathways. A clinico-pathologic study of 12 cases. Karkouche R, Bachet JB, Sandrini J, Mitry E, Penna C, Côté JF, Blons H, Penault-Llorca F, Rougier P, Saint André JP, Emile JF. *Eur J Gastroenterol Hepatol*. 2012 Dec;24(12):1430-7. doi: 10.1097/MEG.0b013e3283583c87.

Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia. Nguyen-Khac F, Lambert J, Chapiro E, Grellet A, Mould S, Barin C, Daudignon A, Gachard N, Struski S, Henry C, Penther D, Mossafa H, Andrieux J, Eclache V, Bilhou-Nabera C, Luquet I, Terre C, Baranger L, Mugneret F, Chiesa J, Mozziconacci MJ, Callet-Bauchu E, Veronese L, Blons H, Owen R, Lejeune J, Chevret S, Merle-Beral H, Leblond V; Groupe Français d'Etude de la Leucémie Lymphoïde Chronique et Maladie de Waldenström (GFCLL/MW); Groupe Ouest-Est d'étude des Leucémie Aiguës et Autres Maladies du Sang (GOELAMS); Groupe d'Etude des Lymphomes de l'Adulte (GELA). *Haematologica*. 2013 Apr;98(4):649-54. doi: 10.3324/haematol.2012.070458. Epub 2012 Oct 12.

Recurrent inactivating mutations of ARID2 in non-small cell lung carcinoma. Manceau G, Letouzé E, Guichard C, Didelot A, Cazes A, Corté H, Fabre E, Pallier K, Imbeaud S, Le Pimpec-Barthes F, Zucman-Rossi J, Laurent-Puig P, **Blons H**. *Int J Cancer*. 2013 May 1;132(9):2217-21. doi: 10.1002/ijc.27900. Epub 2012 Nov 20.

Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. André T, Blons H, Mabro M, Chibaudel B, Bachet JB, Tournigand C, Bennamoun M, Artru P, Nguyen S, Ebenezer C, Aissat N, Cayre A, Penault-Llorca F, Laurent-Puig P, de Gramont A; GERCOR. *Ann Oncol*. 2013 Feb;24(2):412-9. doi: 10.1093/annonc/mds465. Epub 2012 Oct 5.

Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2). Cadranet J, Mauguén A, Faller M, Zalcman G, Buisine MP, Westeel V, Longchamps E, Wislez M, Coudert B, Daniel C, Chetaille B, Michiels S, Blons H, Solassol J, De Fraipont F, Foucher P, Urban T, Lacroix L, Poulot V, Quoix E, Antoine M, Danton G, Morin F, Chouaid C, Pignon JP. *J Thorac Oncol*. 2012 Oct;7(10):1490-502.

Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. Didelot A, Le Corre D, Luscan A, Cazes A, Pallier K, Emile JF, Laurent-Puig P, **Blons H**. *Exp Mol Pathol*. 2012 Jun;92(3):275-80. doi: 10.1016/j.yexmp.2012.03.001. Epub 2012 Mar 7.

Dual blockade of epidermal growth factor receptor-induced pathways: a new avenue to treat metastatic colorectal cancer. Laurent-Puig P, Manceau G, Zucman-Rossi J, **Blons H**. *J Clin Oncol*. 2012 May 1;30(13):1550-2. doi: 10.1200/JCO.2011.40.1190. Epub 2012 Mar 12. No abstract available.

TWIST1 a new determinant of epithelial to mesenchymal transition in EGFR mutated lung adenocarcinoma. Pallier K, Cessot A, Côté JF, Just PA, Cazes A, Fabre E, Danel C, Riquet M, Devouassoux-Shisheboran M, Ansieau S, Puisieux A, Laurent-Puig P, **Blons H**. *PLoS One*. 2012;7(1):e29954. doi: 10.1371/journal.pone.0029954. Epub 2012 Jan 17.

Prediction of response to anticancer treatment as simple as the resolution of ordinary differential equations? Laurent-Puig P, Manceau G, Boige V, **Blons H**. *Gut*. 2012 May;61(5):637-8. doi: 10.1136/gutjnl-2011-301767. Epub 2011 Dec 26. No abstract available.

Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: a comprehensive study of Caucasian non-smokers. Just PA, Cazes A, Audebourg A, Cessot A, Pallier K, Danel C, Vacher-Lavenu MC, Laurent-Puig P, Terris B, **Blons H**. *Lung Cancer*. 2012 Jun;76(3):309-15. doi: 10.1016/j.lungcan.2011.11.004. Epub 2011 Dec 6.

MicroRNA and colorectal cancer. Corté H, Manceau G, Blons H, Laurent-Puig P. *Dig Liver Dis*. 2012 Mar;44(3):195-200. doi: 10.1016/j.dld.2011.10.010. Epub 2011 Nov 21. Review.

DeltaN TP63 reactivation, epithelial phenotype maintenance, and survival in lung squamous cell carcinoma. Pallier K, Cazes A, El Khattabi L, Lecchi C, Desroches M, Danel C, Riquet M, Fabre-Guillevin E, Laurent-Puig P, **Blons H**. *Tumour Biol*. 2012 Feb;33(1):41-51. doi: 10.1007/s13277-011-0239-5. Epub 2011 Oct 11.

Microsatellite instability analysis in uterine cavity washings as a screening tool for endometrial cancer in Lynch syndrome. Bouquier J, Blons H, Narjoz C, Lécuru F, Laurent-Puig P, Bats AS. *Fam Cancer*. 2011 Dec;10(4):655-7. doi:

10.1007/s10689-011-9470-x.

Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3. Borget I, Cadranet J, Pignon JP, Quoix E, Coudert B, Westeel V, Dansin E, Madelaine J, Madroszyk A, Friard S, Daniel C, Morin F, Chouaid C; ERMETIC Collaborative Group. *Eur Respir J*. 2012 Jan;39(1):172-9. doi: 10.1183/09031936.00201210. Epub 2011 Jun 9.

Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: a total of 5550 exons sequenced by 15 molecular French laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in non-small cell lung carcinoma [ERMETIC] project--part 1). Beau-Faller M, Degeorges A, Rolland E, Mounawar M, Antoine M, Poulot V, Mauguen A, Barbu V, Coulet F, Prétet JL, Bièche I, Blons H, Boyer JC, Buisine MP, de Fraipont F, Lizard S, Olschwang S, Saulnier P, Prunier-Mirebeau D, Richard N, Danel C, Brambilla E, Chouaid C, Zalcman G, Hainaut P, Michiels S, Cadranet J. *J Thorac Oncol*. 2011 Jun;6(6):1006-15. doi: 10.1097/JTO.0b013e318211dcee.

Functional assessment of p53 in chronic lymphocytic leukemia. Le Garff-Tavernier M, Blons H, Nguyen-Khac F, Pannetier M, Brissard M, Gueguen S, Jacob F, Ysebaert L, Susin SA, Merle-Béral H. *Blood Cancer J*. 2011 Feb;1(2):e5. doi: 10.1038/bcj.2011.3. Epub 2011 Feb 25. No abstract available.

[p16: molecular mechanisms involved in the carcinogenesis of various organs]. Pallier K, Laurent-Puig P, **Blons H**. *Ann Pathol*. 2010 Nov;30(5 Suppl 1):100-2. doi: 10.1016/j.annpat.2010.07.031. Epub 2010 Sep 29. French. No abstract available.

Oncogenic mutations as predictive factors in colorectal cancer. Lièvre A, Blons H, Laurent-Puig P. *Oncogene*. 2010 May 27;29(21):3033-43. doi: 10.1038/onc.2010.89. Epub 2010 Apr 12. Review.